Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | BRD2 | P25440 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | PGK1 | P00558 | 3/20 | 0.40 |
| ▸ | PGK2 | P07205 | 3/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21802668 | 1.00 | MEN1 (0.47) | MEN1KMT2ALMNAKDM4EUGT2B7 | |
| SCHEMBL2921664 | 0.83 | HDAC4 (0.42) | KDM4EPTPN5 | |
| SCHEMBL3919972 | 0.82 | PTGS2 (0.46) | MEN1KMT2ALMNAKDM4EUGT2B7 | |
| SCHEMBL3919970 | 0.82 | PTGS2 (0.46) | MEN1KMT2ALMNAKDM4EUGT2B7 | |
| SCHEMBL5375384 | 0.82 | MEN1 (0.44) | MEN1KMT2ALMNAKDM4EUGT2B7 | |
| SCHEMBL8792478 | 0.80 | MEN1 (0.47) | MEN1KMT2ALMNAKDM4EUGT2B7 | |
| SCHEMBL31295635 | 0.80 | MEN1 (0.43) | MEN1KMT2ALMNAKDM4EUGT2B7 | |
| SCHEMBL8988941 | 0.80 | ENPP2 (0.50) | MEN1KMT2ALMNAKDM4EUGT2B7 | |
| SCHEMBL29967289 | 0.80 | MEN1 (0.47) | MEN1KMT2ALMNAKDM4EUGT2B7 | |
| SCHEMBL28874730 | 0.80 | TAAR1 (0.42) | HTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10882819-B2 | Synthesis of novel intermediate(s) for preparing rivastigmine | Cadila Corporate Campus (IN) | 2021-01-05 | — | — | US | disclosed |
| US-20200095195-A1 | SYNTHESIS OF NOVEL INTERMEDIATE(S) FOR PREPARING RIVASTIGMINE | CADILA PHARMACEUTICALS, LTD. (IN) | 2020-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882819-B2 | Synthesis of novel intermediate(s) for preparing rivastigmine | ACHE, SQLE, BCHE | MEN1 588/4885KMT2A 649/4885LMNA 2127/4885 |
| US-20200095195-A1 | SYNTHESIS OF NOVEL INTERMEDIATE(S) FOR PREPARING RIVASTIGMINE | ACHE, SQLE, BCHE | MEN1 588/4885KMT2A 649/4885LMNA 2127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.